Cancer incidence and mortality in patients treated either with RAI or thyroidectomy for hyperthyroidism

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 10, 2015, Pages 3710-3717

  Ryödi, Essi ^a,b   Metso, Saara ^a,b   Jaatinen, Pia ^a,b,c   Huhtala, Heini ^d   Saaristo, Rauni ^a   Välimäki, Matti ^e   Auvinen, Anssi ^d  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c SEINÄJOKI CENTRAL HOSPITAL   (Finland)

^d School of Health Sciences   (United States)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE;

ADULT; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FINLAND; FINN (CITIZEN); FOLLOW UP; HAZARD RATIO; HUMAN; HYPERTHYROIDISM; KIDNEY CANCER; MAJOR CLINICAL STUDY; MALE; MIGRATION; PRIORITY JOURNAL; RESPIRATORY TRACT CANCER; RISK ASSESSMENT; STOMACH CANCER; THYROID CANCER; THYROIDECTOMY; UNIVERSITY HOSPITAL; ADVERSE EFFECTS; AGED; INCIDENCE; MIDDLE AGED; MORTALITY; NEOPLASMS; REGISTER; RISK FACTOR;

ADULT; AGED; FEMALE; FINLAND; HUMANS; HYPERTHYROIDISM; INCIDENCE; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASMS; REGISTRIES; RISK FACTORS; THYROIDECTOMY;

EID: 84943774041     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-1874     Document Type: Article

References (28)

1. Metso S, Auvinen A, Huhtala H, Salmi J, Oksala H, Jaatinen P. Increased cancer incidence after radioiodine treatment for hyperthyroidism. Cancer. 2007;109:1972-1979.
2. Holm LE, Hall P, Wiklund K, et al. Cancer risk after iodine-131 therapy for hyperthyroidism. J Natl Cancer Inst. 1991;83:1072-1077.
3. Hieu TT, Russell AW, Cuneo R, et al. Cancer risk after medical exposure to radioactive iodine in benign thyroid diseases: A metaanalysis. Endocr Relat Cancer. 2012;19:645-655.
4. Franklyn JA, Maisonneuve P, Sheppard M, Betteridge J, Boyle P. Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: A population-based cohort study. Lancet. 1999;353: 2111-2115.
5. Goldman MB. Thyroid diseases and breast cancer. Epidemiol Rev. 1990;12:16-28.
6. Hoffman DA, McConahey WM, Fraumeni JF Jr, Kurland LT. Cancer incidence following treatment of hyperthyroidism. Int J Epidemiol. 1982;11:218-224.
7. Pukkala E. Finland cancer registration. In: Cancer Atlas of Northern Europe. Helsinki, Finland: Cancer Society Of Finland; 2001:50-51.
8. Moeller LC, Führer D. Thyroid hormone, thyroid hormone receptors, and cancer: A clinical perspective. Endocr Relat Cancer. 2013; 20:R19-R29.
9. Hellevik AI, Asvold BO, Bjøro T, Romundstad PR, Nilsen TI, Vatten LJ. Thyroid function and cancer risk: A prospective population study. Cancer Epidemiol Biomarkers Prev. 2009;18:570-574.
10. Vestergaard P. Smoking and thyroid disorders-A meta-analysis. Eur J Endocrinol. 2002;146:153-161.
11. CentanniM,MarignaniM,Gargano L, et al. Atrophic body gastritis in patients with autoimmune thyroid disease: an underdiagnosed association. Arch Intern Med. 1999;159:1726-1730.
12. Dahlberg PA, Karlsson FA, Lundqvist G. High serum gastrin levels in thyrotoxic patients. Clin Endocrinol (Oxf). 1981;14:125-131.
13. Watson SA, Grabowska AM, El-Zaatari M, Takhar A. Gastrin-active participant or bystander in gastric carcinogenesis? Nat Rev Cancer. 2006;6:936-946.
14. Venturi S, Venturi A, Cimini D, Arduini C, Venturi M, Guidi A. A new hypothesis: iodine and gastric cancer. Eur J Cancer Prev. 1993; 2:17-23.
15. Kurtz RC, Sherlock P. The diagnosis of gastric cancer. Semin Oncol. 1985;12:11-18.
16. Abnet CC, Fan JH, Kamangar F, et al. Self-reported goiter is associated with a significantly increased risk of gastric noncardia adenocarcinoma in a large population-based Chinese cohort. Int J Cancer. 2006;119:1508-1510.
17. Venturi S. Is there a role for iodine in breast diseases? Breast. 2001; 10:379-382.
18. Carlé A, Pedersen IB, Knudsen N, et al. Epidemiology of subtypes of hyperthyroidism in Denmark: A population-based study. Eur J Endocrinol. 2011;164:801-809.
19. Chen YK, Lin CL, Chang YJ, et al. Cancer risk in patients with Graves' disease: A nationwide cohort study. Thyroid. 2013;23:879-884.
20. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19: 1167-1214.
21. Pazaitou-Panayiotou K, Perros P, Boudina M, et al. Mortality from thyroid cancer in patients with hyperthyroidism: The Theagenion Cancer Hospital experience. Eur J Endocrinol. 2008;159:799-803.
22. Belfiore A, Garofalo MR, Giuffrida D, et al. Increased aggressiveness of thyroid cancer in patients with Graves' disease. J Clin Endocrinol Metab. 1990;70:830-835.
23. Pellegriti G, Belfiore A, Giuffrida D, Lupo L, Vigneri R. Outcome of differentiated thyroid cancer in Graves' patients. J Clin Endocrinol Metab. 1998;83:2805-2809.
24. Franklyn JA. The management of hyperthyroidism. N Engl J Med. 1994;330:1731-1738.
25. Bahn Chair RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011;21:593-646.
26. Goldman MB, Maloof F, Monson RR, Aschengrau A, Cooper DS, Ridgway EC. Radioactive iodine therapy and breast cancer. A follow-up study of hyperthyroid women. Am J Epidemiol. 1988;127: 969-980.
27. Sund R. Quality of the Finnish Hospital Discharge Register: A systematic review. Scand J Public Health. 2012;40:505-515.
28. Institute for Statistical and Epidemiological Cancer Research. Finnish Cancer Registry. http://www.cancer.fi/syoparekisteri/en/statistics/cancer-statistics/. Updated April 2, 2015.